ARTL (Artelo Biosciences) EBIT per Share : $-2.78 (TTM As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Artelo Biosciences EBIT per Share?

Artelo Biosciences's EBIT per Share for the three months ended in Sep. 2024 was $-0.37. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.78.

During the past 3 years, the average EBIT per Share Growth Rate was 43.90% per year. During the past 5 years, the average EBIT per Share Growth Rate was 38.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Artelo Biosciences's EBIT per Share or its related term are showing as below:

ARTL' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -390.2 Med: -76.9 Max: 45.3
Current: 43.9

During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of Artelo Biosciences was 45.30% per year. The lowest was -390.20% per year. And the median was -76.90% per year.

ARTL's 3-Year EBIT Growth Rate is ranked better than
91.54% of 1241 companies
in the Biotechnology industry
Industry Median: 2.9 vs ARTL: 43.90

Artelo Biosciences's EBIT for the three months ended in Sep. 2024 was $-1.20 Mil.

Artelo Biosciences EBIT per Share Historical Data

The historical data trend for Artelo Biosciences's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artelo Biosciences EBIT per Share Chart

Artelo Biosciences Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-22.14

-18.97

-5.97

-3.56

-3.14

Artelo Biosciences Quarterly Data
	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial															-0.89	-0.82	-0.81	-0.78	-0.37

Artelo Biosciences EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Artelo Biosciences's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-9.289	/	2.960
=	-3.14

Artelo Biosciences's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.195	/	3.228
=	-0.37

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.78

Artelo Biosciences (NAS:ARTL) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Artelo Biosciences EBIT per Share Related Terms

Thank you for viewing the detailed overview of Artelo Biosciences's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Artelo Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artelo Biosciences Inc (NAS:ARTL) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

505 Lomas Santa Fe, Suite 160, Solana Beach, CA, USA, 92075

Website

https://www.artelobio.com

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.

Executives

Gregory D. Gorgas	director, officer: See Remarks	888 PROSPECT, SUITE 210, LA JOLLA CA 92037
Tamara A Seymour	director	C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Gregory Reyes	director	200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922
Matsui Connie	director	3030 CALLAN RD, SAN DIEGO CA 92121
John W Beck	director	C/O RITTER PHARMACEUTICALS, INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067
Robert Martin Emanuele	director
David J Moss	10 percent owner	C/O PEGASI ENERGY RESOURCES CORPORATION, 218 N. BROADWAY, SUITE 204, TYLER TX 75702
Georgia Erbez	director	6300 DUMBARTON CIRCLE, FREMONT CA 94555
Steven Kelly	director	C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Douglas Blayney	director	C/O ARTELO BIOSCIENCES, INC., 888 PROSPECT ST, SUITE 210, LA JOLLA CA 92037
Peter Michael O'brien	10 percent owner	C/O ARTELO BIOSCIENCES, INC., 888 PROSPECT ST, SUITE 210, LA JOLLA CA 92037